SATKARTAR Sat Kartar Q4 FY26 results (Jan–Mar 2026) and concall
Sat Kartar Life Limited reported a strong FY26, with revenue exceeding ₹200 crores and significant growth in EBITDA and PAT. The company is strategically expanding into the hospital segment, with its first 30-bed facility operational and ambitious targets for bed count and revenue. While facing initial working capital challenges and pending regulatory approvals for its US subsidiary, management remains confident in achieving aggressive growth and margin expansion through product diversification, AI integration, and strategic collaborations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 40.0%, net profit up 125.0% against the same quarter last year.
| Line item | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|
| Revenue | 75 | 76 | 87 | 88 | 105 +40% |
| EBITDA | 6 | 6 | 9 | 10 | 14 +133% |
| Net profit | 4 | 4 | 6 | 8 | 9 +125% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
